TRANSGENOMIC INC
Form 8-K
May 07, 2014

T	IN	TT	\mathbf{FI}) 5	T	Δ	ΓF	S

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):


May 7, 2014

TRANSGENOMIC, INC.

(Exact name of registrant as specified in its charter)

Delaware 000-30975 911789357 (State of Incorporation) (Commission File Number) (IRS Employer Identification Number)

12325 Emmet Street, Omaha, Nebraska 68164 (Address of principal executive offices) (Zip Code)



Item 2.02 Results of Operations and Financial Condition

On May 7, 2014, Transgenomic, Inc. issued a press release announcing its financial results for the first quarter 2014. A copy of the press release is being furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information referenced in this Current Report on Form 8-K (including Exhibit 99.1 referenced in Item 9.01 below) is being "furnished" under "Item 2.02. Results of Operations and Financial Condition" and, as such, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information set forth in this Current Report on Form 8-K (including Exhibit 99.1 referenced in Item 9.01 below) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended (the "Securities Act"), except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(4) 4	v hı	hito
(d) E	. X I I I	bits.

(99.1) Press release dated May 7, 2014, announcing Transgenomic, Inc.'s financial results for the first quarter 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 7, 2014 TRANSGENOMIC, INC.

By: /s/ Mark P. Colonnese

Mark P. Colonnese
Chief Financial Officer